The Healthcare Distribution Management Association (HDMA) presented its first Distribution Management Award to AmerisourceBergen Packaging Group (ABPG) and Pfizer Pharmaceuticals for its Toviaz™ Physician Sample Package Optimization project. The award, presented at the association’s 2010 Distribution Management Conference & Technology Expo in Baltimore, recognizes member companies’ efforts to improve the efficiency and effectiveness of the healthcare supply chain and enhance trading partner relationships.
Pfizer’s Toviaz, a treatment for overactive bladders, was introduced to the market in 2008 using a child-resistant starter pack for physician samples. In partnership with ABPG company Anderson Packaging, the companies worked together to improve upon this design by transitioning to a more comprehensive package design, using ABPG’s IntuiDose™ child-resistant compliance-prompting format. This enhanced design helped Pfizer to deliver the medication more effectively and cost-efficiently. The improvements resulted in savings in the Toviaz physician sample program and a more patient-friendly product. The new packaging helped to lower processing and operation costs and led to more efficient transportation and distribution.
The Distribution Management Award is the successor to HDMA’s iBusiness Solution and Innovation for Success Awards. HDMA presents the award to a member company or companies that demonstrate the value of distribution by developing creative, results-oriented programs and processes in areas ranging from technology and operations to trade and promotional planning that benefit the healthcare supply chain, customers and consumers, and engage in successful trading partner relationships.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.